Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atypical antipsychotics in the managed care era.

A D Loebel1, S R Botts, B I Feldman

  • 1Albert Einstein College of Medicine, Bronx, NY, USA.

The American Journal of Managed Care
|December 8, 1997
PubMed
Summary

New atypical antipsychotics offer significant long-term benefits for schizophrenia treatment, potentially reducing overall healthcare costs despite higher initial prices. These advanced medications are becoming first-line treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.

Journal of psychopharmacology (Oxford, England)·2008
Same author

Olanzapine-induced diabetes mellitus.

The Annals of pharmacotherapy·2001
Same author

Clozapine-induced hypersalivation.

The Annals of pharmacotherapy·2000
Same author

Gabapentin and lamotrigine in bipolar disorder.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999
Same author

The deficit state in first-episode schizophrenia.

The American journal of psychiatry·1994
Same author

Duration of psychosis and outcome in first-episode schizophrenia.

The American journal of psychiatry·1992

Area of Science:

  • Psychiatry and Pharmacology

Background:

  • A new class of atypical antipsychotic drugs has emerged for schizophrenia treatment.
  • These represent a major advancement since the 1950s, with increasing use as first-line agents.

Purpose of the Study:

  • To review the role of atypical antipsychotics in schizophrenia management.
  • To compare their efficacy and cost-effectiveness against conventional medications.

Main Methods:

  • Review of current literature on atypical antipsychotics.
  • Pharmacoeconomic analysis of treatment costs and benefits.

Main Results:

  • Atypical antipsychotics show promise for improved long-term outcomes when used early in schizophrenia.
  • Despite higher acquisition costs, they may reduce the overall financial burden of the illness.

Conclusions:

  • Atypical antipsychotics are a significant therapeutic development in schizophrenia.
  • Their early adoption may lead to better patient outcomes and potential cost savings.

Related Experiment Videos